ICR Retina Dept. participates in LumiThera’s LIGHTSITE II study for treatment of atrophic AMD

Medical content revised by - Last revision 10/11/2021
ICR Retina Dept. participates in LumiThera’s LIGHTSITE II study for treatment of atrophic AMD

Medical device company LumiThera this week announced the final results of the LIGHTSITE II clinical trial in patients with dry age-related macular degeneration. The prospective, double-masked, randomized, multicenter, prospective study was conducted at eight leading retina centers in Europe, including ICR.

The study aimed to test the effectiveness of photobiomodulation (PBM) treatment with three sessions every four months. It enrolled 44 individuals, with a mean age of 74 years and a mean duration of dry or atrophic AMD of 3.7 years from diagnosis. In total, 32 eyes were included in the group receiving PBM treatment and 19 eyes in the group receiving sham placebo treatment, all with at least one post-treatment visit.

Promising findings

The results showed a statistically significant improvement in the primary endpoint of corrected visual acuity (CVAcc) at nine months from baseline in PBM-treated patients. Also, no safety issues were identified after three rounds of PBM treatment administered at four-month intervals.

In a separate analysis, participants who completed all 27 PBM treatment visits planned according to the protocol were evaluated (not all patients were able to attend all visits due to the COVID-19 pandemic). A significant improvement in corrected visual acuity (CVAcc) at nine months from baseline was observed in PBM-treated participants. Thus, the average improvement in vision for the PBM group over the placebo-treated group at nine months was estimated to be approximately 4 letters versus a gain of 0.5 letters in the placebo-treated group.

Conclusions of the LIGHTSITE II study

The results show a steady improvement over time in corrected visual acuity measurements by administering PBM treatment at shorter intervals compared to the results of the LIGHTSITE I study, where some remission was observed between treatments when treatments were administered every six months. Thus, treatment intervals every four months allow benefits to be maintained more consistently.

Participation of the ICR Retina team in the study

Dr. Jürgens, ICR’s medical director, was one of the retina specialists who participated in the LumiThera study. As he explains, “The data showed that 35% of PBM-treated participants who completed all visits had an improvement of 5 more letters on the standard visual chart, which is more than double the percentage of participants in the placebo-treated group. These improvements in vision in subjects with atrophic AMD using Valeda treatments may have a positive impact on their quality of life.”

Thus, these data suggest that Valeda light delivery system may be a safe, noninvasive treatment opportunity for patients with atrophic AMD currently with few treatment options. However, due to the limited size of the study, all potential benefits will need to be further confirmed by larger studies.

Related articles

Age-Related Macular Degeneration (ARMD)

Age-related macular degeneration or ARMD is a disease that affects the central area of the retina,  the macula. As its name suggests, it is a degenerative disease that progresses with age. What is age-related macular degeneration? Age-related macular degeneration affects the central area of the retina, the macula, and causes central vision problems, difficulty recognizing […]

Photodynamic therapy

Treatment of subretinal neovascularitzation. Skin and eye protection is required  for 24 hours.

5 ways to help prevent macular degeneration

Elderly people are at a higher risk of suffering from age-related macular degeneration (ARMD), one of the leading blindness causes in developed countries. This disease affects central vision and limits reading and writing abilities, besides causing problems in recognizing faces. Luckily, there are a few measures that can be undertaken in order to reduce the […]

How does age affect our eyes?

As we get older our eyes do too, and they present changes that we must control to have good eye health. In celebration of 2020: the year of the eye, the American Academy of Ophthalmology has published the most common age-related eye changes.

Do you have any questions?

Contact us or request an appointment with one of our specialists.

Visit us at:

ICR Pau Alcover

C. Pau Alcover 67
08017 Barcelona See map

ICR Ganduxer Headquarters

c/Ganduxer,117
08022 Barcelona See map

ICR Terrassa

77, Del Nord St.
08221 Terrassa See map

ICR Service at Clínica Ntra. Sra. del Remei

c/ de l'Escorial,148
08024 Barcelona See map

Clínica Bonanova Surgical Center

Passeig Bonanova, 22
08022 Barcelona See map

Clinica Bonanova Tests and Treatments

c/ Mandri, 63
08022 Barcelona See map

ICR Pau Alcover

Telephone number (+34) 93 378 23 19

Opening hours:
Monday to Friday from 8 am to 9 pm. Saturday from 8 am to 2 pm.

How to get there More information

ICR Ganduxer Headquarters

Telephone number 93 254 79 20
Emergencies phone number: 93 418 72 27

Opening hours:
Monday to Friday 8 a.m. to 9 p.m.
Saturdays 9 a.m. to 2 p.m.

How to get there More information

ICR Terrassa

Telephone number +34 93 736 34 40

Opening hours:
Monday to Friday from 8:30 a.m. to 2 p.m. and 3 p.m. to 8 p.m.

How to get there More information

ICR Service at Clínica Ntra. Sra. del Remei

Telephone number 902 10 10 50

Opening hours:
Every day from 3 p.m. to 8 p.m. and Friday mornings from 10 a.m. to 2 p.m.

How to get there More information

Clínica Bonanova Surgical Center

Telephone number 934 34 09 25

Opening hours:
Monday to Friday from 7:30 a.m. to 8:30 p.m.

How to get there More information

Clinica Bonanova Tests and Treatments

How to get there More information